Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Receivables (2020 - 2025)

Cellebrite DI's Receivables history spans 6 years, with the latest figure at $183.5 million for Q4 2025.

  • Quarterly Receivables rose 12.12% to $183.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $183.5 million through Dec 2025, up 12.12% year-over-year, with the annual reading at $183.5 million for FY2025, 12.12% up from the prior year.
  • Receivables came in at $183.5 million for Q4 2025, up from $163.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $183.5 million in Q4 2025 to a low of $89.5 million in Q4 2023.
  • The 5-year median for Receivables is $160.3 million (2022), against an average of $147.4 million.
  • Year-over-year, Receivables tumbled 44.15% in 2023 and then surged 82.87% in 2024.
  • Cellebrite DI's Receivables stood at $139.8 million in 2021, then rose by 14.69% to $160.3 million in 2022, then crashed by 44.15% to $89.5 million in 2023, then skyrocketed by 82.87% to $163.7 million in 2024, then grew by 12.12% to $183.5 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Receivables are $183.5 million (Q4 2025), $163.7 million (Q4 2024), and $89.5 million (Q4 2023).